sodium glucose cotransporter-2 (SGLT2) inhibitors

Overview

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of glucose-lowering therapies used primarily in type 2 diabetes mellitus. They act by blocking SGLT2 in the proximal renal tubule, reducing renal glucose reabsorption and promoting urinary glucose excretion. Beyond their glycemic effects, this drug class has become clinically important because of consistent cardiovascular and renal benefits observed across multiple patient populations, particularly in type 2 diabetes, heart failure, and chronic kidney disease.

In contemporary practice, SGLT2 inhibitors are often discussed alongside other cardiometabolic therapies such as glucagon-like peptide-1 agonists, finerenone, metformin, and statins. Recent research has focused on their effects on heart failure risk, Blood Pressure, kidney outcomes, and broader cardiovascular protection, including in patients with arterial hypertension, coronary artery disease, and chronic renal insufficiency. Individual agents in the class include empagliflozin and dapagliflozin, which are frequently used as representative SGLT2 inhibitors in clinical and translational studies.

Focus of Latest Publications

Recent investigations have focused on the cardiovascular and renal protective effects of SGLT2 inhibitors across diverse patient populations and clinical scenarios. Studies have demonstrated benefits in heart failure with both preserved and reduced ejection fraction, including improved diastolic function after transcatheter aortic valve implantation and reduced mortality when initiated early following acute myocardial infarction. In patients with diabetes and end-stage kidney disease, SGLT2i exposure was associated with lower all-cause mortality, reduced sepsis risk, and fewer hospitalizations compared to dipeptidyl peptidase-4 inhibitors. These agents have also shown renoprotective effects in diabetic kidney disease and preserved kidney function, with evidence suggesting that acute changes in estimated glomerular filtration rate may inform long-term clinical benefit in chronic kidney disease populations.

Metabolic effects and glycemic control remain central to SGLT2i efficacy in real-world practice. Monotherapy with SGLT2 inhibitors achieved the highest rates of glycemic control in Hispanic populations, with rates exceeding 85% achieving target hemoglobin A1c levels. Blood pressure reduction represents a key mechanism, though the magnitude of reduction varies with patient-specific factors including baseline characteristics and comorbidities. However, these agents are associated with increased genitourinary infection risk—including urinary tract infections and genital tract infections—particularly when combined with dipeptidyl peptidase-4 inhibitors, though this adverse effect profile appears population-dependent.

Combination therapy strategies have emerged as areas of active investigation. Combined use of SGLT2 inhibitors with glucagon-like peptide-1 receptor agonists has shown potential for synergistic benefits in metabolic dysfunction-associated steatotic liver disease, with evidence suggesting superior liver fibrosis outcomes and cardiovascular protection compared to monotherapy. Similarly, co-administration with finerenone demonstrated enhanced renal protection in immunoglobulin A nephropathy compared to monotherapy, while combination with statins showed promising effects on ejection fraction in ischemic heart disease patients.

Emerging applications have broadened beyond traditional cardiovascular and metabolic indications. SGLT2 inhibitors have been investigated for their potential roles in reducing seizure risk, slowing progression of early-stage pulmonary malignancies, improving survival in bladder cancer patients, and providing neuroprotective benefits in mild cognitive impairment. In patients with Type 1 diabetes and chronic kidney disease, these agents were observed to be used in clinical practice and associated with favorable outcome patterns, though evidence remains limited. Additionally, despite concerns about weight and muscle loss, SGLT2 inhibitors were associated with lower incidence of frailty-related events compared to dipeptidyl peptidase-4 inhibitor therapy in heart failure patients, suggesting potential benefits that warrant further investigation in vulnerable populations.